Millennium Pharmaceuticals Ortho Biotech, a division of Janssen-Cilag
emerging therapies for relapsed and refractory lymphoid neoplasms
Moderator: P.J. Rosen (Los Angeles, USA)

Introduction: therapy for relapsed and refractory lymphoid neoplasms
P.J. Rosen (Los Angeles, USA)

Diffuse large B-cell lymphoma
M. Pfreundschuh (Homburg, DE)

Multiple myeloma
P. Leif Bergsagel (Scottsdale, USA)

Mantle cell lymphoma
A.H. Goy (Hackensack, USA)

Follicular lymphoma
A. Hagenbeek (Amsterdam, NL)

THERAPY FOR RELAPSED AND REFRACTORY LYMPHOID NEOPLASMS
P.J. Rosen1
1Hematology and Oncology, Tower Cancer Research Foundation, Beverly Hills, CA, United States

Front-line management of lymphoma and multiple myeloma is often very successful and potentially curative in the case of Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. Unfortunately, relapses of therapy for relapsed lymphoid malignancies and multiple myeloma are not as favorable, with the majority of patients eventually becoming refractory to therapy. The introduction of therapeutic strategies such as nonmyeloablative allogeneic transplants and new targeted therapies has shown promise in changing the natural history of these disorders but has made their management increasingly complex. In this symposium, a group of distinguished European and American physicians will discuss emerging treatment strategies for Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Multiple Myeloma. Their presentations will use interactive case presentations to introduce a critical discussion of the various new options available for this population of patients.